Skip to main content

Volume 16 Supplement 1

Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts

Meeting abstracts

Publication charges for this supplement were funded by 3P Solution, Milan, Italy. PAA has/had a consultant/advisory role for BMS, Roche-Genentech, MSD, Array, Novartis, Amgen, Merck Serono, Pierre Fabre, Incyte, NewLink Genetics, Genmab, Medimmune. He also received research funds from BMS, Roche-Genentech, Array. SD have received grants funding from Lytix Biopharma, and honorarium for consulting/advisory activity from Lytix Biopharma, Eisai, Inc., StemImmune, Astrazeneca, and Nanobiotix. SD declares no conflics of interest related to the content of this supplement. RD has intermittent, project focused consulting and/or advisory relationships with Novartis, Merck Sharp & Dhome (MSD), Bristol-Myers Squibb (BMS), Roche, Amgen, Takeda, Pierre Fabre outside the submitted work. MP declares that he is part of the advisory board for BMS, MSD, Novartis, Array, Incyte, NewLink Genetics and have received honoraria from BMS and MSD. IP was a consulatant for Amgen, Novartis, Hoffman-La Roche and Abbvie. CB, GM and EW declare that they have no competing interest.

Naples, Italy29 November - 2 December 2017

Edited by Paolo A. Ascierto, Carlo Bifulco, Sandra Demaria,  Reinhard Dummer, Giuseppe Masucci, Michael Postow, Igor Puzanov and Ena Wang

  1. Authors: David Carbone, Michael Sharpnack, Kai He, Lisa H. Butterfield, Alexander M. M. Eggermont, Maria Gonzalez-Cao, Niki Karachaliou, Guillermo Crespo, Erika Aldeguer, Ana Drozdowskyj, Ana Giménez-Capitán, Cristina Teixidó, Miguel Angel Molina-Vila, Santiago Viteri Ramírez, Salvador Martin Algarra, Elisabeth Pérez-Ruiz…
    Citation: Journal of Translational Medicine 2018 16(Suppl 1):4

Annual Journal Metrics